Therapeutic use of hydrogen molecules
View Patent ↗The invention concerns a kit for preventing or treating oxidative stress in humans or animals by means of therapeutically active hydrogen molecules. The hydrogen molecules are formed by reacting a base metal with aqueous acids or bases and by reacting a saline hydride with water or aqueous acids.
1. A kit for prophylaxis or treatment of oxidative stress in humans and animals, wherein the kit comprises a first component including a base metal for targeted chemical synthesis of therapeutically active hydrogen molecules by reaction with aqueous acid, and a second component, wherein the second component includes at least one acid which is chemically inert with respect to the base metal of the first component, wherein the kit includes adjuvants for an oral form of administration, and wherein the kit includes 0.1 mg to 20 mg magnesium as said base metal, and 1 mg to 1 g of acetylsalicylic acid as said acid in the second component.
2. The kit according to claim 1 , characterized in that therapeutically active hydrogen molecules are formed by combining the base metal with the acid under aqueous conditions.
3. A kit for prophylaxis or treatment of oxidative stress in humans and animals using therapeutically active hydrogen molecules, wherein the kit comprising a first component including a base metal for targeted chemical synthesis active hydrogen molecules by reaction with an aqueous base, and a second component includes at least one base which is chemically inert with respect to the base metal of the first component, wherein the kit includes 0.1 mg to 20 mg magnesium as said base metal, and 1 mg to 1 g of said base selected from the group consisting of potassium hydroxide and sodium hydroxide.
4. The kit according to claim 3 , characterized in that the therapeutically active hydrogen molecules are formed by combining the base metal of the first component with an aqueous base of the second component.
5. The kit according to claim 3 , characterized in that the kit includes acetylcysteine as another component.
6. The kit according to claim 1 , characterized in that the first component is formulated jointly with, or independently from, the second component.
7. The kit according to claim 6 , wherein the first and second components are formulated for simultaneous, consecutive, or time-delayed administration within 60 minutes.
8. The kit according to claim 3 , characterized in that the first component is formulated jointly with, or independently from, the second component.
9. The kit according to claim 8 , wherein the first and second components are formulated for simultaneous, consecutive, or time-delayed administration within 60 minutes.
10. The kit according to claim 1 , wherein the kit or its individual components are formulated as a lozenge, tablet, powder, or capsule for direct oral administration or for indirect administration in an aqueous solvent or administration medium.
11. The kit according to claim 3 , wherein the kit or its individual components are formulated as a lozenge, tablet, powder, or capsule for direct oral administration or for indirect administration in an aqueous solvent or administration medium.
12. The kit of claim 2 , wherein when the base metal or saline hydride is combined with with the acid under aqueous conditions and administered to a human or animal, at least 0.4 mmol or 0.8 mg of molecular hydrogen per day is supplied to the human or animal.
13. The kit of claim 4 , wherein when the base metal of the first component is combined with the aqueous base of the second component and administered to a human or animal, at least 0.4 mmol or 0.8 mg of molecular hydrogen per day is supplied to the human or animal.